Harnessing the Potential of Phospholipids as Pharmaceutical Excipients: A Versatile Platform for Customized Drug Delivery Systems. (PubMed, Drug Dev Ind Pharm) - Oct 26, 2026 - "Doxil and AmBisome demonstrate reductions in cardiotoxicity and nephrotoxicity, respectively. Ionizable lipid nanoparticles containing DSPC enable siRNA delivery in Patisiran and mRNA-vaccine delivery in Comirnaty, although their lipid compositions differ...Phospholipids represent a programmable excipient platform used in numerous approved lipid-based drug products. Advances in synthetic lipid engineering, AI-guided design, and personalised medicine are expected to expand their impact across gene therapy, biologics, and long-acting therapeutics."
Journal • Review • Cardiovascular • Gene Therapies
|
|
Annal Thamaraiselvi Joseph; Saravanan Ravindran
|